Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Profit After Tax (2022 - 2025)

TriSalus Life Sciences' Profit After Tax history spans 4 years, with the latest figure at -$9.8 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 3.51% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$39.2 million, down 30.56%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • Profit After Tax reached -$9.8 million in Q4 2025 per TLSIW's latest filing, up from -$10.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$1.4 million in Q3 2023 to a low of -$35.6 million in Q4 2023.
  • Average Profit After Tax over 4 years is -$11.0 million, with a median of -$9.2 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: surged 82.39% in 2023, then tumbled 350.65% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$22.5 million in 2022, then tumbled by 58.1% to -$35.6 million in 2023, then surged by 71.64% to -$10.1 million in 2024, then rose by 3.51% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Profit After Tax are -$9.8 million (Q4 2025), -$10.8 million (Q3 2025), and -$8.3 million (Q2 2025).